FREE Case Review (866) 588-0600

Public Citizen Demands ‘Black Box Warning’ on Antipsychotic Meds

A public watchdog group has petitioned the FDA to require new ‘black box warnings’ to be added to the labeling of dopamine agonist class antipsychotic drugs regarding an increased risk for compulsive behaviors such as gambling, sexual obsessions and shopping.

The watchdog group Public Citizen is calling on the U.S. Food & Drug Administration (FDA) to add ‘black box warnings’ to antipsychotic drugs from the dopamine agonist class regarding an increased risk for compulsive behaviors such as gambling, sexual obsessions and shopping.

Free Confidential Lawsuit Evaluation: If you or a loved one experienced compulsive behaviors after taking Abilify, you should contact our law firm immediately. You may be entitled to compensation by filing a suit and our lawyers can help.

What’s the Problem?

July 17, 2016 – Public Citizen sent the petition (PDF) last month to Robert Califf, commissioner of the Food & Drug Administration. Medications named in the letter include Requip (ropinorole), Mirapex (pramipexole), Neupro (rotigotine) and 3 other dopamine agonists typically used treat Parkinson’s disease and restless leg syndrome (RLS).

According to Public Citizen, more than 80 studies link these medications to compulsive behaviors. Scientists believe the behaviors are caused by the way the drugs affect dopamine levels in the brain and interact with a receptor known as “D3.”

“As studies have shown, as many as one in five patients taking a dopamine agonist drug may develop certain impulse-control problems and compulsive behaviors,” the letter said. “In their more severe cases, impulse-control problems and compulsive behaviors can have devastating, life-altering effects. Divorces, financial ruin, criminal charges and suicide attempts have been reported in patients using these drugs.”

Studies have also linked Abilify (aripiprazole), a partial dopamine agonist, to an increased risk for compulsive behaviors. Public Citizen’s petition did not focus specifically on the drug, but it did acknowledge data indicating that it was related to these side effects, as well as its effect on the D3 dopamine receptor.

About 1.5 million prescriptions were written for Abilify last year, and the drug generated $6.4 billion in 2013. In May 2016, FDA issued a Drug Safety Communication warning that Abilify, Abilify Maintena and Aristata have been linked to uncontrollable urges to gamble, have sex, binge eat and shop.

Do I Have an Abilify Lawsuit?

The Pharmaceutical Litigation Group at our law firm is an experienced team of trial lawyers that focus on the representation of plaintiffs in Abilify lawsuits. We are handling individual litigation nationwide and currently accepting new compulsive behavior cases in all 50 states.

Free Confidential Case Evaluation: Again, if you or a loved one experienced financial loss, family problems or legal consequences as a result of compulsive gambling while taking Abilify, you should contact our law firm immediately. You may be entitled to a settlement by filing a suit and we can help.

Free Confidential Case Evaluation

Verified 100% Secure SiteTo contact us for a free review of your potential case, please fill out the form below or call us toll free 24 hrs/day by dialing: (866) 588-0600.
*
*
*
Awards & recognition